Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
A Phase I/Phase II Evaluation of Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent, Combined With Infusional Cytarabine in Elderly Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Sponsor: Vion Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
Other Acute Myeloid Leukemia (AML) trials with similar outcome
This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) and is currently terminated or withdrawn. Vion Pharmaceuticals leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Terminated PHASE1_PHASE2
Status: Unknown Status → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Unknown Status PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vion Pharmaceuticals
- Viron Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .